Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC

Xilio Therapeutics, Inc.

2024-Q2 EPS reported -$0.73 revenue$2,357,000

Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.
Cash and equivalents $74.9M at June 30, 2024 (up from $44.7M Dec 2023); runway into Q2 2025.
Initiated Phase 2 trial of XTX101 + atezolizumab in MSS CRC; data expected Q4 2024.
Phase 1B dose expansion for XTX301 started; Phase 1A dose escalation ongoing with no DLTs.
Promoted Chris Frankenfield to CFO while continuing as COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.